Drug intelligence / Profile preview

CordIn

Development stage: Phase 2
Lead developer: Gamida Cell
Modality: Stem Cell Therapies → Cell Therapies
Administration: Intravenous

Overview

CordIn is a cryopreserved stem/progenitor cell-based product developed by Gamida Cell. It is composed of ex vivo expanded allogeneic umbilical cord blood (UCB)-derived purified CD133+ cells. The drug is being investigated for allogeneic stem cell transplantation in patients with hemoglobinopathies, including sickle cell disease and thalassemia, with the aim of evaluating its safety and efficacy.

Beyond the preview

Go deeper on CordIn.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CordIn.

Explore the full profile